title: [Validity of a fixed atenolol/hydrochlorothiazide/amiloride combination (100/25/2.5 mg) in the therapy of essential arterial hypertension].
authors.forename: A
authors.initials: A
authors.lastname: Salvadeo
authors.forename: G
authors.initials: G
authors.lastname: Villa
authors.forename: S
authors.initials: S
authors.lastname: Segagni
authors.forename: G
authors.initials: G
authors.lastname: Moroni
authors.forename: F
authors.initials: F
authors.lastname: Poggio
mesh_terms: D000293:Adolescent; D000328:Adult; D000584:Amiloride / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D006852:Hydrochlorothiazide; D001262:Atenolol; D000584:Amiloride
vernacular_title: Validità della associazione fissa atenololo/idroclorotiazide/amiloride (100/25/2.5 mg) nella terapia dell'ipertensione arteriosa essenziale.